Table 2 Clinical characteristics by boost modality (propensity score matched)
Clinical characteristics | Overall | SIB | Brachy | SMD |
|---|---|---|---|---|
Number (%) | ||||
Number | 162 | 81 | 81 | Â |
HPV status | Â | Â | Â | 0.164 |
 Negative | 21 (13.0) | 10 (12.3) | 11 (13.6) |  |
 Positive | 140 (86.4) | 71 (87.7) | 69 (85.2) |  |
 Unknown | 1 (0.6) | 0 (0.0) | 1 (1.2) |  |
Age ≥ median (62 years) | 85 (52.5) | 41 (50.6) | 44 (54.3) | 0.074 |
Tumour stage* | Â | Â | Â | 0.079 |
 I-II | 10 (6.2) | 5 (6.2) | 5 (6.2) |  |
 III | 18 (11.1) | 8 (9.9) | 10 (12.3) |  |
 IV | 134 (82.7) | 68 (84.0) | 66 (81.5) |  |
Tumour site | Â | Â | Â | 0.584 |
 Base of tongue | 90 (55.6) | 34 (42.0) | 56 (69.1) |  |
 Tonsil | 66 (40.7) | 44 (54.3) | 22 (27.2) |  |
 Other | 6 (3.7) | 3 (3.7) | 3 (3.7) |  |
Performance status at start of radiotherapy |  |  |  |  < 0.001 |
 0 | 144 (88.9) | 72 (88.9) | 72 (88.9) |  |
 1 | 16 (9.9) | 8 (9.9) | 8 (9.9) |  |
 2 | 2 (1.2) | 1 (1.2) | 1 (1.2) |  |
Male gender | 127 (78.4) | 63 (77.8) | 64 (79.0) | 0.030 |
Concurrent medical treatment | Â | Â | Â | 0.094 |
 Cetuximab | 80 (49.4) | 41 (50.6) | 39 (48.1) |  |
 Cetuximab + Cisplatin | 7 (4.3) | 4 (4.9) | 3 (3.7) |  |
 Cisplatin | 55 (34.0) | 26 (32.1) | 29 (35.8) |  |
 None | 20 (12.3) | 10 (12.3) | 10 (12.3) |  |
Induction chemotherapy | 45 (27.8) | 23 (28.4) | 22 (27.2) | 0.028 |
Medical treatment (concurrent or induction) | 144 (88.9) | 72 (88.9) | 72 (88.9) |  < 0.001 |
Cisplatin containing medical treatment | 90 (55.6) | 45 (55.6) | 45 (55.6) |  < 0.001 |